Nurix Therapeutics (NRIX) SEC Filings: History & Chart

Nurix Therapeutics, Inc.(NRIX)

Biotechnology · Brisbane, CA

$22.60-0.28 (-1.22%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Brisbane, CA

317 employees

www.nurixtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Arthur T. Sands

View full financials

Form	Filing Date	Accepted	Document
4	Oct 2, 2026	Oct 2, 2026	View filing
SC 13G	Sep 23, 2026	Sep 23, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
4	Sep 1, 2026	Sep 1, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
4	Aug 5, 2026	Aug 5, 2026	View filing
4	Aug 5, 2026	Aug 5, 2026	View filing
4	Aug 4, 2026	Aug 4, 2026	View filing
4	Aug 3, 2026	Aug 3, 2026	View filing
SC 13G	Jul 31, 2026	Jul 31, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
10-Q	Jul 9, 2026	Jul 9, 2026	View filing
8-K	Jul 9, 2026	Jul 9, 2026	View filing
4	Jul 2, 2026	Jul 2, 2026	View filing
4	Jun 25, 2026	Jun 25, 2026	View filing
4	Jun 25, 2026	Jun 25, 2026	View filing
8-K	Jun 11, 2026	Jun 11, 2026	View filing
8-K	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
4	May 15, 2026	May 15, 2026	View filing
4	May 15, 2026	May 15, 2026	View filing
4	May 15, 2026	May 15, 2026	View filing
4	May 15, 2026	May 15, 2026	View filing
4	May 15, 2026	May 15, 2026	View filing

SEC Filings

Recent Filings